WallStSmart

Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD)vsPOMDOCTOR LIMITED American Depositary Shares (POM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

POMDOCTOR LIMITED American Depositary Shares generates 1706% more annual revenue ($366.86M vs $20.31M). HKPD leads profitability with a -0.1% profit margin vs -40.6%. HKPD earns a higher WallStSmart Score of 36/100 (F).

HKPD

Hold

36

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 5.0Quality: 5.0

POM

Avoid

28

out of 100

Grade: F

Growth: 6.7Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -66.56

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HKPD2 strengths · Avg: 10.0/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

EPS GrowthGrowth
130.2%10/10

Earnings expanding 130.2% YoY

POM2 strengths · Avg: 9.0/10
Debt/EquityHealth
-0.1910/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
16.2%8/10

16.2% revenue growth

Areas to Watch

HKPD4 concerns · Avg: 2.3/10
Market CapQuality
$6.99M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-0.6%2/10

ROE of -0.6% — below average capital efficiency

Revenue GrowthGrowth
-4.7%2/10

Revenue declined 4.7%

Free Cash FlowQuality
$-106,3932/10

Negative free cash flow — burning cash

POM4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$40.13M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Free Cash FlowQuality
$-16.17M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : HKPD

The strongest argument for HKPD centers on Price/Book, EPS Growth.

Bull Case : POM

The strongest argument for POM centers on Debt/Equity, Revenue Growth. Revenue growth of 16.2% demonstrates continued momentum.

Bear Case : HKPD

The primary concerns for HKPD are Market Cap, Return on Equity, Revenue Growth.

Bear Case : POM

The primary concerns for POM are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

HKPD profiles as a turnaround stock while POM is a growth play — different risk/reward profiles.

POM is growing revenue faster at 16.2% — sustainability is the question.

HKPD generates stronger free cash flow (-106,393), providing more financial flexibility.

Monitor PHARMACEUTICAL RETAILERS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HKPD scores higher overall (36/100 vs 28/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

Hong Kong Pharma Digital Technology Holdings Limited is a pioneering company at the intersection of biotechnology and digital healthcare, focusing on the integration of cutting-edge technology with pharmaceutical services to enhance patient outcomes and streamline healthcare delivery. Leveraging advanced digital solutions and data analytics, the company optimizes drug development processes and improves operational efficiencies, positioning itself as a critical player in the evolving healthcare landscape. With a strong commitment to health technology advancement and the cultivation of strategic alliances, Hong Kong Pharma is poised to meet the demands of both domestic and global markets while driving innovation across its pharmaceutical service offerings.

POMDOCTOR LIMITED American Depositary Shares

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

Pomdoctor Limited, offers an online B2C portal to sell pharmaceutical products. The company is headquartered in Guangzhou, China.

Visit Website →

Want to dig deeper into these stocks?